Drug metabolizing enzyme and transporter gene variation, nicotine metabolism, prospective abstinence, and cigarette consumption

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Bergen, Andrew W ^a   Michel, Martha ^b   Nishita, Denise ^a   Krasnow, Ruth ^a   Javitz, Harold S ^a   Conneely, Karen N ^c   Lessov Schlaggar, Christina N ^d   Hops, Hyman ^e   Zhu, Andy Z X ^f   Baurley, James W ^g   McClure, Jennifer B ^h   Hall, Sharon M ^b   Baker, Timothy B ⁱ   Conti, David V ^j   Benowitz, Neal L ^k   Lerman, Caryn ^l   Tyndale, Rachel F ^m   Swan, Gary E ^e,n  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OREGON RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g BioRealm LLC ^*  (United States)

^h GROUP HEALTH RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF WISCONSIN MADISON   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; DRUG METABOLIZING ENZYME AND TRANSPORTER; NICOTINE; PEPTIDE TRANSPORTER 1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CBR1 GENE; CHST13 GENE; CHST8 GENE; CYP2A6 GENE; CYP2D6 GENE; CYP4F3 GENE; DMET GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LUNG CANCER; MALE; METABOLIC PARAMETERS; METABOLISM; NICOTINE METABOLISM; NICOTINE METABOLITE RATIO; NORMAL HUMAN; POST HOC ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLC15A1 GENE; SLCO1B1 GENE; SMOKING; SMOKING CESSATION; SPG7 GENE; XDH GENE; ALLELE; GENETIC ASSOCIATION STUDY; GENETIC VARIATION; GENETICS; MIDDLE AGED; RISK FACTOR;

ADULT; ALLELES; CYTOCHROME P-450 CYP2A6; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; NICOTINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; SMOKING CESSATION;

EID: 84940421719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126113     Document Type: Article

References (48)

1. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug metabolism and disposition: the biological fate of chemicals 24: 1212-1217.
2. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. (1996) Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. The Journal of pharmacology and experimental therapeutics 277: 1010-1015. PMID: 8627511
3. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, et al. (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical pharmacology and therapeutics 76: 64-72. PMID: 15229465
4. Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, et al. (2011) Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20: 234-238.
5. Lerman C, Schnoll RA, Hawk LW, Cinciripinni P, George TP, Wileyto EP, et al. (2015) A Randomized Placebo-controlled Trial to Test a Genetically-informed Biomarker For Personalizing Treatment for Tobacco Dependence. Lancet Respir Med 3:131-138. doi: 10.1016/S2213-2600(14)70294-2 PMID: 25588294
6. Falcone M, Jepson C, Benowitz N, Bergen AW, Pinto A, Wileyto EP, et al. (2011) Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatmentseeking smokers. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 13: 498-503.
7. Bloom J, Hinrichs AL, Wang JC, von Weymarn LB, Kharasch ED, Bierut LJ, et al. (2011) The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenetics and genomics 21: 403-416. doi: 10.1097/FPC.0b013e328346e8c0 PMID: 21597399
8. Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, et al. (2013) Biomarkers for smoking cessation. Clinical pharmacology and therapeutics 93: 526-538. doi: 10.1038/clpt.2013.57 PMID: 23588313
9. Swan GE, Benowitz NL, Jacob P 3rd, Lessov CN, Tyndale RF, Wilhelmsen K, et al. (2004) Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res 7: 435-448. PMID: 15527659
10. Swan GE, Hudmon KS, Jack LM, Hemberger K, Carmelli D, Khroyan TV, et al. (2003) Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 12: 994-1005.
11. Deeken J (2009) The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Ther 11: 260-268. PMID: 19479659
12. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 31: 231-242.
13. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. (2010) Behavioral counseling and varenicline treatment for smoking cessation. American journal of preventive medicine 38: 482-490. doi: 10.1016/j.amepre.2010.01.024 PMID: 20409497
14. Hall SM, Humfleet GL, Gorecki JA, Munoz RF, Reus VI and Prochaska JJ (2008) Older versus younger treatment-seeking smokers: differences in smoking behavior, drug and alcohol use, and psychosocial and physical functioning. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 10: 463-470.
15. Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA and Prochaska JJ (2009) Extended treatment of older cigarette smokers. Addiction 104: 1043-1052. doi: 10.1111/j.1360-0443.2009.02548.x PMID: 19392908
16. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. (2008) A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 10: 717-729.
17. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. (2007) Efficacy of bupropion alone and in combination with nicotine gum. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 9: 947-954.
18. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. (2009) A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Archives of general psychiatry 66: 1253-1262. doi: 10.1001/archgenpsychiatry.2009.142 PMID: 19884613
19. Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. (2014) Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nature genetics 46: 736-741. doi: 10.1038/ng.3002 PMID: 24880342
20. Miller SA, Dykes DD and Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215. PMID: 3344216
21. Nishita DM, Jack LM, McElroy M, McClure JB, Richards J, Swan GE, et al. (2009) Clinical trial participant characteristics and saliva and DNA metrics. BMC medical research methodology 9: 71. doi: 10.1186/1471-2288-9-71 PMID: 19874586
22. Rabe-Hesketh S, Skrondal A and Gjessing HK (2008) Biometrical modeling of twin and family data using standard mixed model software. Biometrics 64: 280-288. PMID: 17484777
23. Conneely KN and Boehnke M (2010) Meta-analysis of genetic association studies and adjustment for multiple testing of correlated SNPs and traits. Genetic epidemiology 34: 739-746. doi: 10.1002/gepi.20538 PMID: 20878715
24. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. (2013) Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and genomics 23: 94-103. doi: 10.1097/FPC.0b013e32835cdabd PMID: 23249876
25. Rubin DB (1987) Multiple Imputation for Nonresponse in Surveys. New York: J. Wiley & Sons.
26. Heatherton TF, Kozlowski LT, Frecker RC and Fagerstrom KO (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British journal of addiction 86: 1119-1127. PMID: 1932883
27. Fagerstrom K (2012) Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco 14: 75-78.
28. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. American journal of human genetics 81: 559-575. PMID: 17701901
29. Yang J, Lee SH, Goddard ME and Visscher PM (2011) GCTA: a tool for genome-wide complex trait analysis. American journal of human genetics 88: 76-82. doi: 10.1016/j.ajhg.2010.11.011 PMID: 21167468
30. Conneely KN and Boehnke M (2007) So Many Correlated Tests, So Little Time! Rapid Adjustment of P Values for Multiple Correlated Tests. American journal of human genetics 81.
31. Barrett JC, Fry B, Maller J and Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England) 21: 263-265.
32. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ and de Bakker PI (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics (Oxford, England) 24: 2938-2939.
33. Gauderman WJ and Morrison JM (2006) QUANTO: A computer program for power and sample size calculations for genetic-epidemiology studies.
34. Coordinators NR (2014) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 42: D7-17. doi: 10.1093/nar/gkt1146 PMID: 24259429
35. Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A, et al. (2005) Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenetics and genomics 15: 609-624. PMID: 16041240
36. Sim SC (2014) CYP2A6 allele nomenclature. In: Sim S. C., editor editors. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Karolinska Institutet.
37. Bloom AJ, Harari O, Martinez M, Zhang X, McDonald SA, Murphy SE, et al. (2013) A compensatory effect upon splicing results in normal function of the CYP2A6∗14 allele. Pharmacogenetics and genomics 23: 107-116. doi: 10.1097/FPC.0b013e32835caf7d PMID: 23292114
38. Messina ES, Tyndale RF and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. The Journal of pharmacology and experimental therapeutics 282: 1608-1614. PMID: 9316878
39. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, et al. (2008) Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Human mutation 29: 679-688. doi: 10.1002/humu.20698 PMID: 18360915
40. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. (2010) Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nature genetics 42: 448-453. doi: 10.1038/ng.573 PMID: 20418888
41. Chang MH, Lindegren ML, Butler MA, Chanock SJ, Dowling NF, Gallagher M, et al. (2009) Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. American journal of epidemiology 169: 54-66. doi: 10.1093/aje/kwn286 PMID: 18936436
42. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. (2006) Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical pharmacology and therapeutics 79: 600-608. PMID: 16765148
43. Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. (2014) Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 109: 128-137. doi: 10.1111/add.12353 PMID: 24033696
44. Ring HZ, Valdes AM, Nishita DM, Prasad S, Jacob P 3rd, Tyndale RF, et al. (2007) Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenetics and genomics 17: 1007-1015. PMID: 18004205
45. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, et al. (2007) CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62: 635-641. PMID: 17223085
46. Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C and Tyndale RF (2007) CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16: 1312-1314.
47. Bloom AJ, Murphy SE, Martinez M, von Weymarn LB, Bierut LJ and Goate A (2013) Effects upon invivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption. Pharmacogenetics and genomics 23: 62-68. doi: 10.1097/FPC.0b013e32835c3b48 PMID: 23211429
48. Chenoweth MJ, Zhu AZ, Sanderson Cox L, Ahluwalia JS, Benowitz NL and Tyndale RF (2014) Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. Pharmacogenetics and genomics 24: 172-176. doi: 10.1097/FPC.0000000000000031 PMID: 24448396